Chart-Typ:
Zeitraum:
| ICL To Acquire Bartek Ingredients In Two Phase Deal | WASHINGTON (dpa-AFX) - ICL Group Ltd (ICL), a chemical and specialty mineral company, on Thursday announced that it has entered into a definitive agreement to acquire Bartek Ingredients Inc.... ► Artikel lesen |
| Dividendenbekanntmachungen (02.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABACUS GLOBAL MANAGEMENT INC US00258Y1047 0,2 USD 0,1722 EUR ABC ARBITRAGE SA FR0004040608 - 0,1 EUR B2GOLD CORP CA11777Q2099 0... ► Artikel lesen |
| ICL Group Ltd Q3 Sales Increase | WASHINGTON (dpa-AFX) - ICL Group Ltd (ICL) reported earnings for third quarter of $115 millionThe company's earnings came in at $115 million, or $0.09 per share. This compares with $113 million... ► Artikel lesen |
| ADC Therapeutics SA: ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large ... | ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of... ► Artikel lesen |
| ADC Therapeutics SA: ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial | Company to host corporate webcast to share updated data on December 3, 2025
LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT)... ► Artikel lesen |
| ADC Therapeutics SA: ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update | Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026
Updated data from Phase 2 IIT of ZYNLONTA®... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPANJAARD LIMITED finden Sie auf Wallstreet Online.